|
Clinical Sample 1
| | | |
|
Novelty seeking
| | | |
|
A1 absent
|
Val absent
|
19
|
56.2 ± 14.0
|
| |
Val present
|
69
|
51.8 ± 18.3
|
|
A1 present
|
Val absent
|
19
|
47.4 ± 13.6
|
| |
Val present
|
39
|
51.0 ± 15.1
|
|
DRD2 main effect
| | |
F (1,142) = 2.38, p = 0.125
|
|
COMT main effect
| | |
F (1,142) = 0.015, p = 0.901
|
|
DRD2 × COMT
| | |
F (1,142) = 1.62, p = 0.206
|
|
Harm avoidance
| | | |
|
A1 absent
|
Val absent
|
19
|
70.8 ± 15.9
|
| |
Val present
|
69
|
67.0 ± 21.0
|
|
A1 present
|
Val absent
|
19
|
66.9 ± 23.4
|
| |
Val present
|
39
|
66.3 ± 19.8
|
|
DRD2 main effect
| | |
F (1,142) = 0.356, p = 0.552
|
|
COMT main effect
| | |
F (1,142) = 0.319, p = 0.573
|
|
DRD2 × COMT
| | |
F (1,142) = 0.165, p = 0.685
|
|
Clinical Sample 2
| | | |
|
Novelty seeking
| | | |
|
A1 absent
|
Val absent
|
16
|
48.3 ± 18.5
|
| |
Val present
|
62
|
47.9 ± 15.9
|
|
A1 present
|
Val absent
|
14
|
46.4 ± 12.5
|
| |
Val present
|
54
|
47.9 ± 14.0
|
|
DRD2 main effect
| | |
F (1,142) = 0.087, p = 0.769
|
|
COMT main effect
| | |
F (1,142) = 0.027, p = 0.870
|
|
DRD2 × COMT
| | |
F (1,142) = 0.088, p = 0.767
|
|
Harm avoidance
| | | |
|
A1 absent
|
Val absent
|
16
|
70.7 ± 18.1
|
| |
Val present
|
62
|
72.3 ± 15.9
|
|
A1 present
|
Val absent
|
14
|
73.1 ± 17.5
|
| |
Val present
|
54
|
69.3 ± 22.1
|
|
DRD2 main effect
| | |
F (1,142) = 0.008, p = 0.928
|
|
COMT main effect
| | |
F (1,142) = 0.082, p = 0.775
|
|
DRD2 × COMT
| | |
F (1,142) = 0.489, p = 0.485
|
